FYN as A Potential Drug Target for Cancer and Neurodegenerative Diseases

Target Name: FYN

NCBI ID: G2534

FYN as A Potential Drug Target for Cancer and Neurodegenerative Diseases

FYN (Fyndelta7) is a protein that is expressed in various tissues throughout the body, including the brain, heart, liver, and peripheral tissues. It is a member of the tyrosine kinase family and is involved in the regulation of cell growth, differentiation, and survival. FYN has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

FYNdelta7 Expression and Functions

FYNdelta7 is a 21-kDa protein that is expressed in a variety of tissues, including the brain, heart, liver, and peripheral tissues. It is predominantly expressed in the brain, where it is found in the postsynaptic terminal of dendrites and in the cell body of neurons. FYNdelta7 is also expressed in other tissues, including the liver, where it is involved in the regulation of glucose metabolism, and the muscle, where it is involved in muscle growth and maintenance.

FYNdelta7 plays a critical role in the regulation of cell growth, differentiation, and survival. It is involved in the development and maintenance of neural stem cells, which are a source of diverse neural cell types that are involved in the development and maintenance of neural function. FYNdelta7 is also involved in the regulation of cell proliferation, as it plays a role in the G1/S transition, which is the process by which cells prepare for cell division.

In addition to its role in cell growth and differentiation, FYNdelta7 is also involved in the regulation of cell survival. It has been shown to play a role in the regulation of apoptosis, which is the process by which cells undergo programmed cell death. FYNdelta7 has been shown to promote apoptosis in a variety of cell types, including cancer cells, neurodegenerative cells, and heart muscle cells.

FYNdelta7 and Cancer

FYNdelta7 has been identified as a potential drug target for cancer due to its involvement in the regulation of cell growth, differentiation, and survival. Many studies have shown that FYNdelta7 is expressed in various types of cancer, including breast, ovarian, and colorectal cancers. Additionally, studies have shown that FYNdelta7 has been involved in the development and progression of cancer, as it has been shown to promote the growth and survival of cancer cells.

One of the potential mechanisms by which FYNdelta7 contributes to cancer is its role in the regulation of angiogenesis, which is the process by which new blood vessels are formed to support the growth and expansion of cancer cells. FYNdelta7 has been shown to play a role in the regulation of angiogenesis and has been shown to promote the growth and survival of cancer cells in a variety of models.

Another potential mechanism by which FYNdelta7 contributes to cancer is its role in the regulation of cell adhesion. Many studies have shown that FYNdelta7 is involved in the regulation of cell-cell adhesion and has been shown to play a role in the development and progression of cancer.

FYNdelta7 and Neurodegenerative Diseases

FYNdelta7 has also been identified as a potential drug target for neurodegenerative diseases due to its involvement in the regulation of cell growth, differentiation, and survival. Many studies have shown that FYNdelta7 is involved in the regulation of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

One of the potential mechanisms by which FYNdelta7 contributes to neurodegenerative diseases is its role in the regulation of axon growth and differentiation. Many studies have shown that FYNdelta7 is involved in the regulation of axon growth and differentiation and has been shown to play

Protein Name: FYN Proto-oncogene, Src Family Tyrosine Kinase

Functions: Non-receptor tyrosine-protein kinase that plays a role in many biological processes including regulation of cell growth and survival, cell adhesion, integrin-mediated signaling, cytoskeletal remodeling, cell motility, immune response and axon guidance. Inactive FYN is phosphorylated on its C-terminal tail within the catalytic domain. Following activation by PKA, the protein subsequently associates with PTK2/FAK1, allowing PTK2/FAK1 phosphorylation, activation and targeting to focal adhesions. Involved in the regulation of cell adhesion and motility through phosphorylation of CTNNB1 (beta-catenin) and CTNND1 (delta-catenin). Regulates cytoskeletal remodeling by phosphorylating several proteins including the actin regulator WAS and the microtubule-associated proteins MAP2 and MAPT. Promotes cell survival by phosphorylating AGAP2/PIKE-A and preventing its apoptotic cleavage. Participates in signal transduction pathways that regulate the integrity of the glomerular slit diaphragm (an essential part of the glomerular filter of the kidney) by phosphorylating several slit diaphragm components including NPHS1, KIRREL1 and TRPC6. Plays a role in neural processes by phosphorylating DPYSL2, a multifunctional adapter protein within the central nervous system, ARHGAP32, a regulator for Rho family GTPases implicated in various neural functions, and SNCA, a small pre-synaptic protein. Participates in the downstream signaling pathways that lead to T-cell differentiation and proliferation following T-cell receptor (TCR) stimulation. Phosphorylates PTK2B/PYK2 in response to T-cell receptor activation. Also participates in negative feedback regulation of TCR signaling through phosphorylation of PAG1, thereby promoting interaction between PAG1 and CSK and recruitment of CSK to lipid rafts. CSK maintains LCK and FYN in an inactive form. Promotes CD28-induced phosphorylation of VAV1. In mast cells, phosphorylates CLNK after activation of immunoglobulin epsilon receptor signaling (By similarity)

More Common Targets